Lei Peng
Associate Research Scientist in NeurosurgeryCards
About
Research
Publications
2026
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Yang L, Renauer P, Tang K, Saskin J, Zhou L, Zou C, Lee S, Fox M, Johnson-Noya S, Weiss B, Deng S, Fang P, Chen B, Sferruzza G, Fooladi S, Zhao K, Park D, Zhang F, Tu J, Chen J, Moliterno J, Gunel M, Peng L, Chen S. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 2026, 652: 740-751. PMID: 41741641, DOI: 10.1038/s41586-026-10149-8.Peer-Reviewed Original ResearchThis study investigates OR7A10-engineered CAR-NK cells, showing they enhance tumor-killing ability, persistence, and survival in solid tumor models, offering a scalable cancer therapy.
2025
A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
Fang Z, Monteiro V, Oh C, Janabi K, Romero L, Ahsan N, Yang L, Peng L, DiMaio D, Lucas C, Chen S. A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity. Nature Biomedical Engineering 2025, 10: 501-516. PMID: 40855125, DOI: 10.1038/s41551-025-01478-6.Peer-Reviewed Original Research
2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai Z, Feng B, McClory S, de Oliveira B, Diorio C, Gregoire C, Tao B, Yang L, Zhao Z, Peng L, Sferruzza G, Zhou L, Zhou X, Kerr J, Baysoy A, Su G, Yang M, Camara P, Chen S, Tang L, June C, Melenhorst J, Grupp S, Fan R. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 2024, 634: 702-711. PMID: 39322664, PMCID: PMC11485231, DOI: 10.1038/s41586-024-07762-w.Peer-Reviewed Original ResearchCAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIn vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy
Peng L, Renauer P, Sferruzza G, Yang L, Zou Y, Fang Z, Park J, Chow R, Zhang Y, Lin Q, Bai M, Sanchez A, Zhang Y, Lam S, Ye L, Chen S. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nature Biotechnology 2024, 43: 752-761. PMID: 38918616, PMCID: PMC11668911, DOI: 10.1038/s41587-024-02282-4.Peer-Reviewed Original Research
News
News
Get In Touch
Contacts
Email